IP Library Granted Patent US 10,653,671
Granted Patent B2
US 10,653,671 · App. 13/834,281 · Granted May 19, 2020

Topical pharmaceutical compositions for treatment of skin damage

Inventors: David Nigel Armstrong (Lawrenceveille, GA); Justin Slagel (Watford, GB)
Assignee: S.L.A. PHARMA, AG
A61K31/4164A61K9/0014A61K9/0031A61K9/06A61K31/192A61K31/24A61K31/245A61K31/355A61K31/407A61K31/4166A61K31/545A61K31/573A61K31/60A61K31/65A61K33/30A61K45/06A61K47/06A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,653,671
App. No.
13/834,281
Granted
May 19, 2020
Kind
B2
Abstract

A topical composition comprising about 5 wt % to about 12.5 wt % of metronidazole or a pharmacologically acceptable salt thereof in a non-aqueous vehicle. The composition may be used in the treatment of skin damage due to inflammatory skin conditions; thermal, chemical or electrical burns; infections or radiation treatment. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect, and thus, side effects observed from systemic administration are avoided.

Claims (16)

1. A method of treating skin in a patient, wherein the skin has been damaged by a second degree, a third degree, or a fourth degree burn wherein the burns are selected from the group consisting of sunburn, burns from cancer therapy radiation, chemical burns, electrical burns, and thermal burns, the method comprising:

topically applying a topical composition to the damaged skin, wherein the topical composition consists essentially of metronidazole in a therapeutically effective concentration of 10 wt % in a pharmacologically acceptable non-aqueous vehicle to treat the skin damaged by said burns, wherein the dosage of metronidazole for each application is from about 125 mg to about 375 mg.

2. The method of claim 1 , wherein the topical composition reduces edema.

3. The method of claim 1 , wherein said vehicle is an organic vehicle.

4. The method of claim 1 , wherein the vehicle comprises at least one hydrocarbon compound.

5. The method of claim 1 , wherein the vehicle comprises a mixture of at least two semi-solid saturated hydrocarbon compounds.

6. The method of claim 1 , wherein the vehicle comprises white petrolatum (USP).

7. The method of claim 1 , wherein said topical composition is in the form of an ointment, lotion, gel, foam or cream.

8. The method of claim 1 , wherein the dosage of metronidazole for each application is about 250 mg.

9. The method of claim 1 , wherein said topical composition is applied between from 2 to 4 times daily.

10. The method of claim 1 , wherein said topical composition has a fluffy texture.

11. The method of claim 10 , wherein said topical composition is obtained by passing metronidazole and white petrolatum through an ointment mill.

12. The method of claim 1 , wherein the topical composition is applied in an application of 2.5 cm 3 .

13. The method of claim 1 , wherein the topical composition has a pH of about 7.

14. The method of claim 1 , wherein the topical composition has a viscosity of from 20,000 to 100,000 mPas.

15. The method of claim 1 , wherein the burn is due to cancer therapy radiation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2013
From: ARMSTRONG, DAVID NIGEL; SLAGEL, JUSTIN
To: S.L.A. PHARMA AG
Reel/Frame 030363/0499 →
Continuity (4)
Continuation In Part 12834198 · Jul 12, 2010
Continuation 10525208
Provisional Application 60406351 · Aug 26, 2002
Related Publication 20130217741A1 · Aug 22, 2013